Norah I. Almanie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Norah I. Almanie has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Meead Awdah
Department of Obstetrics and Gynecology, College of Medicine, King Khalid University, Abha, Saudi Arabia
2 shared publicationsReem Almanie
Department of Obstetrics and Gynecology, Khamis Mushait Maternity and Children’s Hospital, Khamis Mushait, Saudi Arabia
2 shared publicationsAshwaq M. Assiri
Department of Obstetrics and Gynecology, Abha Maternity and Children Hospital, Abha, Saudi Arabia
1 shared publication- Ashwaq M. Assiri
Department of Obstetrics and Gynecology, Abha Maternity and Children Hospital, Abha, Saudi Arabia
1 shared publication Ayman H. Shaamash
Department of Obstetrics and Gynecology, College of Medicine, King Khalid University, Abha, Saudi Arabia
1 shared publication- Ayman Hussien Shaamash
Department of Obstetrics and Gynecology, College of Medicine, King Khalid University, Abha, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 17 October 2026
- Published by Springer Nature in Middle East Fertility Society Journal
- Vol. 31 (1) , 79
Correction: Cabergoline for reducing the incidence of Ovarian Hyperstimulation Syndrome (OHSS) in women undergoing IVF/ICSI: a systematic review and meta-analysis of randomized controlled trials
- 17 October 2026
- Published by Springer Nature in Middle East Fertility Society Journal
- Vol. 31 (1) , 79
Open AccessCorrection: Cabergoline for reducing the incidence of Ovarian Hyperstimulation Syndrome (OHSS) in women undergoing IVF/ICSI: a systematic review and meta-analysis of randomized controlled trials
- Open Access
- 10 September 2026
- Published by Springer Nature in Middle East Fertility Society Journal
- Vol. 31 (1) , 72
Cabergoline for reducing the incidence of Ovarian Hyperstimulation Syndrome (OHSS) in women undergoing IVF/ICSI: a systematic review and meta-analysis of randomized controlled trials
Background: Dopamine agonists are increasingly used to prevent ovarian hyperstimulation syndrome (OHSS), but the evidence remains fragmented. We synthesized comparative evidence on cabergoline for preventing moderate-to-severe OHSS in women undergoing IVF/ICSI, analysing randomized and non-randomized evidence as separate evidence streams. Methods: PubMed/MEDLINE, Embase, and the Cochrane Library were searched from inception to 1 May 2026. Randomized controlled trials (RCTs) and prospective non-randomized comparative studies comparing cabergoline with placebo or no treatment were eligible. Two reviewers independently performed selection, data extraction, and risk-of-bias assessment (RoB 2, ROBINS-I). In accordance with Cochrane guidance, randomized and non-randomized studies were not combined: the pooled estimate from the RCTs constituted the primary analysis, and the non-randomized studies were pooled separately as supportive evidence. Moderate-to-severe OHSS was expressed as an odds ratio (OR) using a random-effects model; certainty was rated with GRADE for each evidence stream. Results: Eight studies (969 women) were included: six RCTs (748 women) and two prospective non-randomized comparative studies (221 women). In the primary analysis restricted to the six RCTs, cabergoline was associated with a lower incidence of moderate-to-severe OHSS (OR 0.41, 95% CI 0.26–0.64; I² = 18%; 138 events). The two non-randomized studies, analysed separately, gave a consistent estimate (OR 0.21, 95% CI 0.07–0.66; I² = 0%). Assuming a baseline risk of 100 per 1,000 women, this corresponds to 57 fewer cases of moderate-to-severe OHSS per 1,000 women (95% CI 34 to 72 fewer). The estimate was robust in leave-one-out analysis (range OR 0.33–0.47) and after excluding the trial subject to an Expression of Concern (OR 0.42, 95% CI 0.25–0.73). No funnel-plot asymmetry was detected (Egger’s P = 0.90), but with six trials publication bias could not be reliably excluded. Clinical pregnancy, live birth, and adverse events were inconsistently reported and were not pooled. Certainty of evidence was Low for the randomized stream and Very low for the non-randomized stream. Conclusions: Low-certainty evidence indicates that cabergoline may reduce the incidence of moderate-to-severe OHSS in women undergoing IVF/ICSI. The available data did not identify a clear adverse signal for clinical pregnancy, live birth, or maternal adverse events, but were insufficient to determine these effects reliably. Cabergoline should be positioned as an adjunctive measure alongside, not instead of, contemporary primary prevention strategies.
- 10 September 2026
- Published by Springer Nature in Middle East Fertility Society Journal
- Vol. 31 (1) , 72
Open AccessCabergoline for reducing the incidence of Ovarian Hyperstimulation Syndrome (OHSS) in women undergoing IVF/ICSI: a systematic review and meta-analysis of randomized controlled trials
Background: Dopamine agonists are increasingly used to prevent ovarian hyperstimulation syndrome (OHSS), but the evidence remains fragmented. We synthesized comparative evidence on cabergoline for preventing moderate-to-severe OHSS in women undergoing IVF/ICSI, analysing randomized and non-randomized evidence as separate evidence streams. Methods: PubMed/MEDLINE, Embase, and the Cochrane Library were searched from inception to 1 May 2026. Randomized controlled trials (RCTs) and prospective non-randomized comparative studies comparing cabergoline with placebo or no treatment were eligible. Two reviewers independently performed selection, data extraction, and risk-of-bias assessment (RoB 2, ROBINS-I). In accordance with Cochrane guidance, randomized and non-randomized studies were not combined: the pooled estimate from the RCTs constituted the primary analysis, and the non-randomized studies were pooled separately as supportive evidence. Moderate-to-severe OHSS was expressed as an odds ratio (OR) using a random-effects model; certainty was rated with GRADE for each evidence stream. Results: Eight studies (969 women) were included: six RCTs (748 women) and two prospective non-randomized comparative studies (221 women). In the primary analysis restricted to the six RCTs, cabergoline was associated with a lower incidence of moderate-to-severe OHSS (OR 0.41, 95% CI 0.26–0.64; I² = 18%; 138 events). The two non-randomized studies, analysed separately, gave a consistent estimate (OR 0.21, 95% CI 0.07–0.66; I² = 0%). Assuming a baseline risk of 100 per 1,000 women, this corresponds to 57 fewer cases of moderate-to-severe OHSS per 1,000 women (95% CI 34 to 72 fewer). The estimate was robust in leave-one-out analysis (range OR 0.33–0.47) and after excluding the trial subject to an Expression of Concern (OR 0.42, 95% CI 0.25–0.73). No funnel-plot asymmetry was detected (Egger’s P = 0.90), but with six trials publication bias could not be reliably excluded. Clinical pregnancy, live birth, and adverse events were inconsistently reported and were not pooled. Certainty of evidence was Low for the randomized stream and Very low for the non-randomized stream. Conclusions: Low-certainty evidence indicates that cabergoline may reduce the incidence of moderate-to-severe OHSS in women undergoing IVF/ICSI. The available data did not identify a clear adverse signal for clinical pregnancy, live birth, or maternal adverse events, but were insufficient to determine these effects reliably. Cabergoline should be positioned as an adjunctive measure alongside, not instead of, contemporary primary prevention strategies.